A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and/or drug) or oral immunotherapy (OIT).

Start Date01 Jun 2025

Sponsor / Collaborator-

NCT06927999

/ Not yet recruitingPhase 2

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).

Start Date01 May 2025

Sponsor / Collaborator

ARS Pharmaceuticals, Inc.

NCT06834165

/ Not yet recruitingPhase 4

A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients with Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.

Start Date30 Apr 2025

Sponsor / Collaborator

ARS Pharmaceuticals, Inc.

100 Clinical Results associated with Adrenaline

100 Translational Medicine associated with Adrenaline

100 Patents (Medical) associated with Adrenaline

69,046

Literatures (Medical) associated with Adrenaline

31 Dec 2025·SCANDINAVIAN CARDIOVASCULAR JOURNAL

Ex vivo resuscitation and evaluation of hearts after 22 minutes of normothermic cardiac arrest

Article

Author: Li, Mei ; Steen, Erik ; Steen, Stig ; Pascevivius, Audrius ; Liao, Qiuming

OBJECTIVE:

The aim was to resuscitate and evaluate hearts ex vivo after 22 min of cardiac arrest with the goal of increasing the number of usable hearts from controlled donation after circulatory death (cDCD).

DESIGN:

Eight pigs (39-61 kg) underwent 22 min of ventricular fibrillation, after which the heart was first perfused in vivo for three minutes with an oxygenated, erythrocyte-containing cardioplegic preservation solution. The heart was then explanted and perfused ex vivo with the same solution for three hours at 18 °C in a transportable heart preservation system. Functional evaluation was performed ex vivo (n = 7), while one heart underwent orthotopic transplantation and was monitored for 24 h.

RESULTS:

The seven hearts evaluated ex vivo easily pumped twice the cardiac output measured in vivo. The transplanted heart maintained normal blood pressure, blood gases, and urine output throughout the 24-hour observation period. At the end of this period the aortic pressure was 104/80 mmHg with a heart rate of 129 beats per minute. Intravenous administration of 20, 40, and 100 µg adrenaline resulted in an aortic pressures of 238/171, 284/196, and 287/201 mmHg with corresponding heart rates of 162, 188, and 223 beats per minute.

CONCLUSION:

Hearts exposed to 22 min of cardiac arrest were successfully resuscitated ex vivo and demonstrated adequate function when evaluated.

01 Nov 2025·TALANTA

Synthesis of ternary heterostructured rice-stick-like Ag/polyoxometalates/nitrogen-doped carbon nanotube hybrids for the sensitive detection of adrenaline

Article

Author: Yang, Xinjian ; Shen, Wei ; Hao, Lin ; Zhang, Yufan ; Liu, Lin

This study presents the innovative design and synthesis of rice-stick-like Ag/polyoxometalates/nitrogen-doped carbon nanotubes (Ag/POM/N-CNTs) using an efficient and mild reduction method. N-CNTs are first synthesized through a self-degrading template method followed by the carbonization of polypyrrole nanotubes (PPy-NTs). The N-CNTs exhibit excellent characteristics, including a high length-to-diameter ratio and an interconnected nanotube structure, which shorten the electron transport distance and enhance electrochemical properties. During the process of loading Ag nanoparticles (Ag NPs) onto the N-CNTs, POM serves as both a reducing and linking agent. The synergistic effect between Ag species and N-CNTs significantly improves the catalytic performance of the nanohybrids. As a result, the Ag/POM/N-CNT-based electrochemical sensor demonstrates exceptional performance in adrenaline detection, with a broad linear range (0.40-700 μM), a low detection limit (0.30 μM, S/N = 3), and a sensitivity of 3.13 μA μM^-1. In addition to these advantages, the composite material also exhibits excellent specificity and stability, strongly indicating the practical application potential of Ag/POM/N-CNTs in adrenaline detection.

01 Nov 2025·BIOSENSORS & BIOELECTRONICS

High accuracy sensor for two-parameter detection of adrenaline and pH in sweat

Article

Author: Zhou, Lianqun ; Wei, Wei ; Kong, Hui ; Li, Anne Ailina ; Zhang, Zhenjie ; Wang, Chenhao ; Tang, Chengchen ; Wang, Qing

Here, we report a wearable device integrating a sweat collection unit and a molecularly imprinted polymer (MIP) - based sensor for the non-invasive detection of adrenaline (AD). In this paper, a new MIP method is proposed, which uses AD molecule as template, and electropolymerizes aniline and 3-aminophenylboronic acid (3-APBA) to form molecular imprinting. Surface modifications, incorporating carbon nanotubes (CNT) and MIP optimization, enhanced the device's specific surface area by 166.45 % (±2.82 %), yielding a wide linear detection range of AD (10^-6 μmol L^-1 to 10³ μmol L^-1). In this study, a three-dimensional response model was constructed by analyzing the current values corresponding to sweat pH levels (4.0-8.0) and AD concentrations, enabling a linear response and accurate prediction of AD levels in sweat. The integrated flexible electronic platform supports real-time data transmission via Bluetooth or NFC to a mobile application, facilitating efficient detection. Comprehensive integration and validation, including artificial sweat testing and correlation with ELISA results, underscore the sensor's potential as a robust and versatile solution for wearable health monitoring.

344

News (Medical) associated with Adrenaline

29 Jun 2025

·www.globenewswire.com

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions. With an intuitive, needle-free design, EURneffy® can help more people confidently use adrenaline when it matters most, supporting fast, reliable emergency treatment and ultimately helping improve the chances of successful outcomes and save lives. EURneffy® offers a longer shelf life (30 months) and superior temperature stability compared to existing adrenaline auto-injectors (AAIs). ALK's Senior Vice President of Commercial Operations in Europe, Flora Beiche-Scholz, said: "Physicians in Germany can now – as the first physicians in Europe – prescribe EURneffy® as an easy-to-bring, user-friendly adrenaline treatment option for patients with life-threatening allergies. With EURneffy®, we aspire to improve the lives of people with severe allergic reactions and facilitate that patients and caregivers consistently carry emergency medication." The EU approval was based on the review of data from the EURneffy® development programme involving more than 700 participants. No serious adverse events were reported in clinical studies with EURneffy®. The extensive clinical pharmacological data of EURneffy® 2 mg was comparable to AAIs, with the pharmacodynamics and pharmacokinetics evaluated across a range of dosing conditions. EURneffy® with a 1 mg dosage for patients weighing 15-30 kg is currently undergoing an EU regulatory review process which is expected to complete in 2026. In Europe, anaphylaxis occurs in up to eight out of every 100,000 people each year, and one in 300 people experiences it at some point in their lives. In emergency situations, uncertainty and hesitation with larger auto-injectors are apparent among those at risk. In November 2024, ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. granting ALK exclusive global rights to commercialise neffy® (including EURneffy® in EU) with exception of the USA, Australia, New Zealand, Japan, and China. In May 2025, the partnership was extended to include a co-promotion agreement in the USA. ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. The content above comes from the network. if any infringement, please contact us to modify.

25 Jun 2025

·investors.aquestive.com

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit , which will be held June 27-29 in Chicago, Ill. The data from these posters was originally presented at the 2025 AAAAI Annual Meeting. If approved by the U.S. Food and Drug Administration (FDA), Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States. Poster presentation details are as follows: Poster Title: The Physicochemical Properties of Anaphylm Under Extreme Temperatures and Real-World Conditions Lead Author: Nils Confer, PhD Presentation Time: Saturday, June 28 from 5:00PM to 7:30PM CST Poster Title: Epinephrine Delivered via Sublingual Film (Anaphylm) Elicits Rapid and Consistent Pharmacokinetic and Pharmacodynamic Responses Lead Author: Carl Kraus, MD Presentation Time: Saturday, June 28 from 5:00PM to 7:30PM CST The abstracts are available on the Company’s website on the Scientific Events page of the Investors section. About Anaphylm™ (epinephrine) Sublingual Film Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the U.S. Food and Drug Administration (FDA). Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate. About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various possible dermatological conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn. Forward-Looking Statement Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, including and the following launch of Anaphylm, if approved by the FDA; that the results of the Company’s clinical studies for Anaphylm are sufficient to support submission of the NDA for approval of Anaphylm by the FDA; the advancement of the Company’s product candidate AQST-108 through clinical development and approval by the FDA for possible various dermatology conditions including alopecia areata; the potential benefits our products and product candidates could bring to patients; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm and AQST-108; risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including with respect to the approval of our filed NDA for Anaphylm, or the failure to receive FDA approval at all for any of our product candidates, including Anaphylm and AQST-108; risk of the Company’s ability to generate sufficient clinical data for approval of our product candidates, including with respect to our pharmacokinetic and pharmacodynamic comparability submission for FDA approval of Anaphylm; risk of the Company’s ability to address the FDA’s comments on the Company’s clinical trials and other concerns identified in the FDA’s Type C meeting minutes and filing review letter for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risk that the FDA may require that an Advisory Committee be required for the approval of Anaphylm and that the Company is able to address any concerns raised by such Advisory Committee or the FDA after review of the advice from the Advisory Committee; risk of the success of any competing products, including generics; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, including under our ATM facility, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund commercialization activities relating to fund future clinical development and commercial activities for our product candidates, including Anaphylm, should these product candidates be approved by the FDA; risk of eroding market share for Suboxone® and risk as a sunsetting product, which accounts for the substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in the U.S. of Anaphylm and our other product candidates, should these product candidates be approved by the FDA, and for our licensed products in the U.S. and abroad; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office (USPTO); risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and products candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against Aquestive including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and rising interest rates; risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on our business; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions; risks related to uncertainties about U.S. government initiatives and their impact on our business, including imposition of tariffs and other trade restrictions; and other unusual items; and other uncertainties affecting us including those described in the "Risk Factors" section and in other sections included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners. Investor Contact: Brian Korb astr partners brian.korb@astrpartners.com

16 Jun 2025

·ir.alk.net

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy. During the EAACI 2025 scientific programme, ALK sponsored two major symposia and participated at several oral sessions, presenting data on the latest innovation in anaphylaxis, children with respiratory allergy, and recent advances in peanut food allergy. The two symposia which both saw major interest from the attendees were: The arrival of nasal adrenaline – an innovation in the treatment of anaphylaxisThis symposium presented the EURneffy® nasal adrenaline spray as a new treatment option designed to address the unmet needs and current challenges in the emergency management of anaphylaxis. This session included compelling real-world data supporting the effectiveness of the nasal adrenaline spray in treating acute anaphylaxis. ALK also presented data demonstrating that the EURneffy® adrenaline nasal spray produces a pharmacological response comparable to intramuscular adrenaline injection in patients with allergic rhinitis. and The evolution of immunotherapy in children – from respiratory to peanut allergy This symposium showcased the latest clinical evidence from ALK’s sublingual allergy immunotherapy tablet portfolio for children suffering from respiratory allergy. The evidence demonstrated that the treatment option can transform allergy care in suitably informed patients and families. Furthermore, it was shown that the disease-modifying effect of allergy immunotherapy (AIT) in children with respiratory allergy is supported by real-life data, with long-term benefits observed for both upper and lower airway disease. In addition, preliminary findings from the ALLIANCE clinical trial were presented that suggest that the peanut SLIT-tablet holds promise as a well-tolerated future treatment option especially for children with peanut allergy. Key phase 1 data from the ongoing peanut PT-01 ALLIANCE trial were also presented and discussed during an oral scientific abstract session. Henriette Mersebach, Executive Vice President of Research & Development at ALK says:“It was a great pleasure to contribute to this year’s EAACI and showcase the important innovations happening at ALK that support our ongoing product launches, as well as new promising research in food allergy. This year, we presented data on anaphylaxis, paediatric respiratory allergy, and food allergy, which is a testament to the dedication and high scientific standards in our company and our continuous focus on helping people living with allergy.” For further information, please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net Attachment Press release_16Jun25_ALK at EAACI

ImmunotherapyPhase 1Clinical Result

100 Deals associated with Adrenaline

External Link

KEGG	Wiki	ATC	Drug Bank
D00095	Adrenaline	C01CA24 B02BC09 S01EA01	DB00668

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Intermittent asthma	United States	Armstrong Pharmaceuticals, Inc.	07 Nov 2018
Mydriasis	United States	Endo Operations Ltd.	07 Dec 2012
Hypersensitivity	United States	Viatris Specialty LLC	22 Dec 1987
Hypersensitivity	United States	Viatris, Inc.	22 Dec 1987
Anesthesia	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Bronchial Spasm	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hemorrhage	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hypotension	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Shock	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Anaphylaxis	China	Grand Pharmaceutical Group	01 Jan 1981
Heart Arrest	China	Grand Pharmaceutical Group	01 Jan 1981
Asthma	United States	Wyeth Consumer Healthcare LLC	08 Nov 1967

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Persistent asthma	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Urticaria	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Hypersensitivity, Immediate	Phase 2	Canada	Aquestive Therapeutics, Inc.	12 Jul 2022
Drug Hypersensitivity	Phase 1	Sweden	Orexo AB	22 Apr 2024
Rhinitis, Allergic	Phase 1	China	ARS Pharmaceuticals, Inc.	17 Mar 2023
Rhinitis, Allergic	Phase 1	China	Pediatrix Therapeutics (Shanghai) Co.,Ltd.	17 Mar 2023
Respiratory Tract Infections	Phase 1	Australia	ARS Pharmaceuticals, Inc.	09 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02722746 (Pilot epinephrine dose-finding study, CTgov)	Phase 1/2	Analgesia \| Hypotension	66	Ropivacaine (Ropivacaine Only Control Group)	xzuwikedem: percent difference = 20.8 (95% CI, -8.9 to 47.3), P-Value = 0.165	-	18 Jun 2025
				Ropivacaine+Epinephrine (Ropivacaine + 2 mcg/mL Epinephrine)
CTIS2024-514037-38-00 (OX640-002, Company_Website) Manual	Not Applicable	Rhinitis, Allergic	30	OX640	hviwfjbdry(qmhpqyvxsb) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. eqqntrudau (wpxgbewpuj ) View more	Positive	10 Jan 2025
				0.3 mg intramuscular epinephrine
GlobeNewswire Manual	Not Applicable	Oral allergy syndrome	-	Anaphylm (with allergen exposure)	pwikzbtbwz(eodzmjrfmk) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. fveprlbkbc (bxgyrhauuh ) Met View more	Positive	24 Oct 2024
				Anaphylm (without allergen exposure)
ACAAI2024	Not Applicable	Rhinitis, Allergic	43	Epinephrine Nasal Spray (ARS-1 2.0 mg)	xxfzcvjelz(ylcitzrgql) = All adverse events were mild tdsiursqaw (swvvcpxzzy )	-	24 Oct 2024
				Intramuscular Epinephrine (0.3 mg)
ACAAI2024	Not Applicable	Food Hypersensitivity	-	Nasal Epinephrine Spray 1 mg	oybiwodxzk(ojxegjtynq) = Adverse events were mild/moderate and resolved quickly nspakggpnp (xfgxyvpdvx )	Positive	24 Oct 2024
				Nasal Epinephrine Spray 2 mg
NCT04207840 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	Phase 4	Asthma \| Anaphylaxis	28	Epinephrine MDI	bnxnoixgde(omqowlpsfz) = ggqilbyjgt dwgdhjeacx (lqoukbcays )	Positive	29 Aug 2024
				Epinephrine IM	bnxnoixgde(omqowlpsfz) = nouimfbnth dwgdhjeacx (lqoukbcays )
NCT03126968 (PROPHET, CTgov)	Phase 2/3	Hemorrhage \| Lung transplant rejection \| Hemoptysis	66	Topical epinephrine (Prophylactic Topical Epinephrine)	zubrvffngh = rbxnhwvkau iyeqzfpbyt (uwsctlanls, lbgemdzhxl - ozrgfylxjw) View more	-	28 Aug 2024
				Placebos (Placebo)	zubrvffngh = hnjcqvcmgx iyeqzfpbyt (uwsctlanls, dolopnwkyu - zzfptpbxhy) View more
GlobeNewswire Manual	Not Applicable	Hypersensitivity	36	Anaphylm™ (epinephrine) Sublingual Film	sgigbjfrzq(djoczndbmd) = pbqczfjxtd iowadlflqj (niovmxceyc ) Met	Positive	25 Jul 2024
				Adrenalin manual intramuscular (IM) injection	sgigbjfrzq(djoczndbmd) = coxvssxpmk iowadlflqj (niovmxceyc ) Met
NCT02722746 (Pilot epinephrine dose-finding study, Pubmed)	Phase 1/2	Hypotension	-	Epidural ropivacaine 0.2% without epinephrine	xvffoexpvm(iyuixqidsj) = vxcaqdgpsx rdtclhgntx (fbajpvfvhr )	Negative	11 Jul 2024
				Epidural ropivacaine 0.2% + 2 µg/mL epinephrine	xvffoexpvm(iyuixqidsj) = tefhmktbct rdtclhgntx (fbajpvfvhr )
ENDO2024	Not Applicable	Diabetic Ketoacidosis	-	Epinephrine infusion	ioojletliy(stroxudipb) = eackyiqwdl myzofkfuhl (qivlgvhaig ) View more	-	01 Jun 2024
				Zosyn 3.375 g IV every 6 hours with IV normal saline at 80ml/hr	ioojletliy(stroxudipb) = redvmkqadh myzofkfuhl (qivlgvhaig ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Adrenaline

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation